Ertapenem
Based on 12 publication(s) in Google Scholar
Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 153832-46-3
- Fòrmula: C22H25N3O7S
- Peso molecular:475.51
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ertapenem
More- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Nat Commun. 2021 Jul 22;12(1):4461. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Dec 2;122(48):e2524436122. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2314514121. [Abstract]
- J Clin Microbiol. 2024 Jun 12;62(6):e0152023. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2023 Sep 5;78(9):2242-2253. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- Adv Ther (Weinh). 2024 Jan 12.
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
Ver todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
β-lactam |
Ertapenem (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B. fragilis (ATCC 25285), B. thetaiotaomicron (ATCC 29741), and Eubacterium lentum (ATCC 43055)
-
Concentration:0-100 μg/mL approximately
-
Incubation Time:48 h
-
Result:Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:S. aureus thigh tissue infection model (DBA/2 mice)[2]
-
Dosage:0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h)
-
Administration:Subcutaneous injection (0.5 mL after infection)
-
Result:Displayed > 3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg. Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
-
Animal Model:Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)[2]
-
Dosage:0-3 mg/kg approximately
-
Administration:Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection)
-
Result:Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of <0.25 mg/kg/dose.
-
Animal Model:CD-1 mice, rats[2]
-
Dosage:10 mg/kg approximately
-
Administration:Intraperitoneal injection (pharmacokinetic assay)
-
Result:Exhibited an AUC0-∞ ranging from 1.8-21.82 μg•hr/mL in tissue in mice following a 10-mg/kg i.p. dose. Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15μg•hr/mL.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 153832-46-3
-
Peso molecular 475.51
-
Fòrmula C22H25N3O7S
-
SMILES
O=C(C(N12)=C(S[C@@H]3CN[C@H](C(NC4=CC=CC(C(O)=O)=C4)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O
-
Synonyms
MK-0826
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Nat Commun
An on-demand, drop-on-drop method for studying enzyme catalysis by serial crystallography. [Abstract]2021 Jul 22;12(1):4461. PMID: 34294694 -
Proc Natl Acad Sci U S A
Antibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations. [Abstract]2025 Dec 2;122(48):e2524436122. PMID: 41296732 -
Proc Natl Acad Sci U S A
In-patient evolution of a high-persister Escherichia coli strain with reduced in vivo antibiotic susceptibility. [Abstract]2024 Jan 16;121(3):e2314514121. PMID: 38190524 -
J Clin Microbiol
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. [Abstract]2024 Jun 12;62(6):e0152023. PMID: 38712928 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians. [Abstract]2023 Sep 5;78(9):2242-2253. PMID: 37522258 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866 -
-
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936
Pureza y Documentación
Referencias
[1]. Kenneth E Aldridge. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis. 2002 Oct;44(2):181-6. [Content Brief]
[2]. C J Gill, et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother. 1998 Aug;42(8):1996-2001. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ertapenem Related Classifications
HY-A0294 Related Classifications
Powered by Bioz